Jul 04, 2019 / 04:00AM GMT
Kosuke Iijima - Chugai Pharmaceutical Co., Ltd. - Department Manager of Foundation Medicine Business Department
[Interpreted] Good afternoon, ladies and gentlemen. I'm Kosuke Iijima, Department Manager of Foundation Medicine Business Department at Chugai Pharmaceutical Co., Ltd. Thank you very much for gathering despite the bad weather today.
Our gene panel testing FoundationOne CDx cancer genomic profile product was approved in December last year. It has been launched and become available for use with National Health Insurance coverage since June this year.
Today, prior to Dr. Muto's presentation, I would like to give you a brief overview of FoundationOne CDx cancer genomic profile product. As you can see here, over the past decade, there has been transformational shift and evolution in the field of oncology. Many things are changing at a very rapid speed. There are a lot of things we cannot cover just on this slide, but still there has been transformational shift in cancer care over the past 10 years.
Cancer is a genomic disease caused by genetic alterations. We have quite a
Chugai Pharmaceutical Co Ltd FoundationOne CDx Information Meeting Transcript
Jul 04, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers